PD-L1 Testing and Clinical Benefit in Patients Treated with CPI

被引：1
|
作者：
Kovacevic, M. [1 ]
Ivanovic, M. [1 ]
Kern, I. [1 ]
Cufer, T. [1 ]
机构：
[1] Univ Clin Golnik, Pathol, Golnik, Slovenia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
PD-L1; CPI; NSCLC;
D O I：
10.1016/j.jtho.2019.08.1679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-30
引用
收藏
页码：S781 / S782
页数：3
相关论文
共 50 条
  • [21] Analysis of Real-World PD-L1 Testing for Clinical Use in Patients with Lung Cancer
    Krigsfeld, G. S.
    Zerba, K.
    Chizhevsky, V.
    Ragheb, J. W.
    White, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 236 - 236
  • [22] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    [J]. TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [23] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    [J]. Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10
  • [24] Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
    Abdel-Rahman, Omar
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 : 75 - 85
  • [25] Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies
    Nagai, Yoshiaki
    Sata, Masafumi
    Ohta, Hiromitsu
    Onuki, Tsugitoshi
    Saito, Tatsuya
    Uchiyama, Ayumi
    Kurosaki, Ayako
    Yoshizumi, Naoko
    Takigami, Ayako
    Nakazawa, Shoko
    Nakayama, Masayuki
    Yamaguchi, Hironori
    Hagiwara, Koichi
    [J]. IMMUNOTHERAPY, 2022, 14 (15) : 1211 - 1217
  • [26] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Hunter, Katerina Ancevski
    Socinski, Mark A.
    Villaruz, Liza C.
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2018, 22 (01) : 1 - 10
  • [27] Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
    Niu, Mengke
    Liu, Yiming
    Yi, Ming
    Jiao, Dechao
    Wu, Kongming
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Clinical implication of PLR and PD-L1 in breast cancer patients
    Wang, S.
    Lu, Q.
    Qin, T.
    Xu, F.
    Zeng, Y.
    Xia, W.
    Zheng, Q.
    Lee, K.
    Zhang, K.
    Qin, G.
    Kong, M. T.
    Hong, R.
    Shi, Y.
    Yuan, Z.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [29] The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide
    Richter, Igor
    Jirasek, Tomas
    Havlickova, Ivana
    Curcikova, Radmila
    Samal, Vladimir
    Dvorak, Josef
    Bartos, Jiri
    [J]. JOURNAL OF BUON, 2018, 23 (06): : 1796 - 1802
  • [30] The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
    Powles, Thomas
    Walker, Jill
    Williams, J. Andrew
    Bellmunt, Joaquim
    [J]. CANCER TREATMENT REVIEWS, 2020, 82
12345